Skip to content
OpenCapital
Get started

Jade Biosciences, Inc. Common Stock JBIO Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

Diluted EPS-$0.19In line
EPS estimate-$0.19

Next report

Aug 12, 2026 (in 2 months)
EPS estimate-$0.66

Financials

Q4 2024

Income statement

See full
Operating income-$35.5M-61.1%
Net income-$47.0M-130%
EPS (diluted)-$14.89-1,912%

Balance sheet

See full
Cash & equivalents$69.4M+195%
Total debt$417.0K-38.2%
Total equity-$46.8M-143%
Total assets$72.8M-42.9%

Cash flow

See full
Operating cash flow-$22.6M-52.8%

Versus estimates

Diluted EPS

Q1 2026-$0.57Miss by $0.05Q4 2025-$0.11Beat by $0.34Q3 2025-$0.48Beat by $0.09Q2 2025-$0.86Miss by $0.43Q1 2025-$0.09Beat by $8.31
Q4 2024-$0.19In line

Ask the moment Jade Biosciences, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Jade Biosciences, Inc. Common Stock report Q4 2024 earnings?
Jade Biosciences, Inc. Common Stock (JBIO) reported Q4 2024 earnings on March 27, 2025 before market open.
What were Jade Biosciences, Inc. Common Stock's Q4 2024 revenue and EPS?
Jade Biosciences, Inc. Common Stock reported diluted EPS of $-0.19 for Q4 2024.
Did Jade Biosciences, Inc. Common Stock beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.19 by $0.00.
Where can I find Jade Biosciences, Inc. Common Stock's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-003750) directly on SEC EDGAR. The filing index links above go to sec.gov.